No connection

Search Results

IMCC vs INM

IMCC
IM Cannabis Corp.
BEARISH
Price
$0.36
Market Cap
$2.2M
Sector
Healthcare
AI Confidence
95%
INM
InMed Pharmaceuticals Inc.
BEARISH
Price
$0.72
Market Cap
$2.4M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
IMCC
--
INM
--
Forward P/E
IMCC
-0.28
INM
-0.11
P/B Ratio
IMCC
-0.8
INM
0.21
P/S Ratio
IMCC
0.04
INM
0.53
EV/EBITDA
IMCC
-3.49
INM
0.57

Profitability

Gross Margin
IMCC
17.7%
INM
29.73%
Operating Margin
IMCC
-31.42%
INM
-258.57%
Profit Margin
IMCC
-20.68%
INM
-170.07%
ROE
IMCC
--
INM
-97.2%
ROA
IMCC
-10.92%
INM
-49.77%

Growth

Revenue Growth
IMCC
17.6%
INM
-26.2%
Earnings Growth
IMCC
--
INM
--

Financial Health

Debt/Equity
IMCC
--
INM
0.06
Current Ratio
IMCC
0.67
INM
5.94
Quick Ratio
IMCC
0.41
INM
4.85

Dividends

Dividend Yield
IMCC
--
INM
--
Payout Ratio
IMCC
0.0%
INM
0.0%

AI Verdict

IMCC BEARISH

IMCC exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9 and the absence of a Graham Number or Altman Z-Score due to negative equity (Price/Book: -0.80). While the company has shown recent revenue growth of 17.6% and a series of EPS 'beats,' these are marginal improvements on a foundation of deep losses and negative margins. The catastrophic 5-year price decline of 99.9% and a current ratio of 0.67 indicate a high risk of insolvency and a lack of investor confidence.

Strengths
Positive YoY revenue growth of 17.60%
Recent quarterly EPS beats (3 of last 4 quarters)
Extremely low Price/Sales ratio (0.04)
Risks
Negative equity as indicated by Price/Book of -0.80
Severe liquidity risk with a Current Ratio of 0.67 and Quick Ratio of 0.41
Persistent negative operating margins (-31.42%)
INM BEARISH

The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across nearly all fundamental health dimensions. While the current ratio is high (5.94), this is offset by a catastrophic profit margin of -170.07% and declining year-over-year revenue growth of -26.20%. The stock is in a clear long-term death spiral, with a 5-year price change of -100% and a technical trend score of 0/100. Without a pivot to profitability or a significant capital infusion, the business model appears unsustainable.

Strengths
Very low Debt/Equity ratio (0.06) indicating minimal long-term debt burden
Strong short-term liquidity with a Current Ratio of 5.94
Positive Gross Margin (29.73%) suggesting the core product has some inherent value
Risks
Critical financial health as evidenced by a 1/9 Piotroski F-Score
Severe operational inefficiency with an Operating Margin of -258.57%
Negative revenue growth (-26.20% YoY) indicating shrinking market share or demand

Compare Another Pair

IMCC vs INM: Head-to-Head Comparison

This page compares IM Cannabis Corp. (IMCC) and InMed Pharmaceuticals Inc. (INM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile